美國食品藥物管理局 (FDA) 對 BrainSee 的 De Novo 上市許可標誌著阿茲海默症診斷的一大進步。BrainSee 憑藉先進的影像處理和醫療人工智能技術，為從遺忘型輕度認知功能障礙 (aMCI) 發展成阿茲海默症的可能性預測樹立了新標準。這一突破是主動腦部健康管理的重要一步，提供了完全非入侵性、方便、全球通用的篩查方案，能夠優先在其他測試或治療之前展開。 三藩市2024年1月15日 /美通社/ — 今天，領先的腦部健康創新公司 Darmiyan, Inc. 宣佈，其首創 BrainSee 的臨床測試 (De Novo) 獲得 FDA 的許可，為對抗阿茲海默症的戰役帶來了關鍵的轉捩點。獲此許可意味著腦部健康領域有的重大進展，同時也擴闊了腦部健康診斷和管理方面尚未開發的市場潛力。 BrainSee 以 40 多年的領先腦部科學為基礎，採用先進的全腦影像分析和醫療人工智能技術，是 Darmiyan 核心專利技術的首個臨床應用。它是一個可擴展性高且完全自動化的軟件平台，結合了標準臨床腦部 MRI 認知評估（這是對記憶力衰退患者的常規非入侵性檢查的一部分），並能夠生成客觀評分，預測患者在 5 年內從 aMCI 發展成阿茲海默症的可能性。BrainSee 填補了逾 1000 万美國人以及全球逾 1 億位正在與 aMCI 抗爭的患者们未被滿足的關鍵需求。隨著全球人口老齡化，預計 BrainSee 的社會經濟影響力將快速和急劇增長。 Continue Reading Darmiyan Darmiyan 創辦人兼行政總裁 Padideh Kamali-Zare 博士表示：「我們的願景是重新定義腦部健康篩查和監測的標準，並以有意義的方式改變患者及其家庭成員的生活。BrainSee 是在這個願景下誕生的首個產品，由我們可信賴的技術基礎設施支援，能夠進一步推動腦部健康領域的轉型和可擴展創新。」… Continue reading Darmiyan 首個用於預測阿茲海默症發展可能性的預後測試 BrainSee 獲 FDA 許可
Tag: Morgan
Darmiyan获得FDA对BrainSee的批准，这是首个能够预测阿尔茨海默病痴呆症发展可能性的预后测试
美国食品药物管理局 (FDA) 对 BrainSee 的 De Novo 批准代表了在阿尔兹海默症诊断上的重大进步。BrainSee 采用了先进的图像处理技术并由医学人工智能提供支持，为从遗忘型轻度认知障碍 (aMCI) 发展到阿尔茨海默病痴呆的可能性设立了新的预测标准。本次突破是主动大脑健康管理的重要一步，提供了全面的非侵入性、便捷且全球适用的筛查解决方案，值得在其他测试和治疗前优先考虑。 旧金山 2024年1月15日 /美通社/ — 今天标志着 Darmiyan, Inc. 对抗阿尔兹海默症取得转折点式成绩，这家领先的脑类医疗创新公司宣布，FDA 已批准了其首款同类产品 BrainSee 的临床测试 (De Novo)。这一批准标志着脑健康领域的一项重大进展，并为尚且无人涉足，但充满潜力的脑类疾病诊断和管理的市场打开了大门。 BrainSee 是首款采用 Darmiyan 专利核心技术的临床应用，该应用基于该公司所累积的逾 40 年先进的大脑科学，并采用高级全脑成像分析技术，由医学人工智能提供支持。这是一款扩展性极强且完全自动化的软件平台，结合标准临床大脑 MRI 和认知分析，即对失忆患者进行常规非侵入性检查，并能得出一个客观评分，预测患者 5 年内从 aMCI 发展为阿尔茨海默痴呆症的可能性。BrainSee 解决了饱受 aMCI 困扰的 1000 万美国人和全球 1 亿患者面临的迫切需求。随着全球人口的老化，BrainSee 的社会经济影响预计也将快速并呈指数级增长。 Continue Reading Logo Darmiyan 创始人兼行政总裁 Padideh Kamali-Zare 博士表示：”我们的愿望是重新定义大脑健康的筛查和监测标准，并为患者及其家人们的生活带去更有意义的影响。BrainSee 是该愿景下的首款产品，在我们坚实的技术基础设施支持下，将进一步推动大脑医疗健康未来的转型和大规模创新。” BrainSee 的早期筛查和风险评估，能够为那些发展为阿尔茨海默氏痴呆症的高危 aMCI… Continue reading Darmiyan获得FDA对BrainSee的批准，这是首个能够预测阿尔茨海默病痴呆症发展可能性的预后测试
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Expensify, Inc. of Class Action Lawsuit and Upcoming Deadline – EXFY
NEW YORK, Jan. 14, 2024 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Expensify, Inc. (“Expensify” or the “Company”) (NASDAQ: EXFY) and certain officers. The class action, filed in the United States District Court for the District of Oregon, and docketed under 23-cv-01784, is on behalf of a class… Continue reading SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Expensify, Inc. of Class Action Lawsuit and Upcoming Deadline – EXFY
“Global Top Brands” Awards Ceremony: Global Witness of Scientific and Technological Innovation
LAS VEGAS, Jan. 12, 2024 /PRNewswire/ — On January 10, 2024, the Global Top Brands Awards Ceremony was held in Las Vegas, USA. Experts, scholars, business leaders, and media elites from the global consumer electronics industry gathered together to witness the new trends in consumer electronics development driven by scientific and technological innovation. With the theme… Continue reading “Global Top Brands” Awards Ceremony: Global Witness of Scientific and Technological Innovation
Tesla stock down on Red Sea delays, rising labor costs and price cuts
An employee of the Tesla Gigafactory Berlin-Brandenburg works on a production line of a Model Y electric vehicle. Patrick Pleul | Picture Alliance | Getty Images Shares of Tesla closed down more than 3% Friday as the stock faced pressure from supply chain delays due to a crisis in the Red Sea, and after offering… Continue reading Tesla stock down on Red Sea delays, rising labor costs and price cuts
Summit Materials Completes Combination with Argos USA
Transaction Creates Unrivaled, Materials Dominant, Platform with National Scale DENVER, Jan. 12, 2024 /PRNewswire/ — Summit Materials, Inc. (NYSE: SUM, “Summit” or the “Company”) announced today that it has successfully completed its $3.2 billion combination with Argos North America Corp. (“Argos USA,” the U.S. operations of Cementos Argos S.A. (CCB.CN, CEMARGOS CB) (“Cementos Argos”)). Shareholders of… Continue reading Summit Materials Completes Combination with Argos USA
Darmiyan recibe la aprobación de la FDA para BrainSee, la primera prueba que permite predecir la probabilidad de progresión a la demencia de Alzheimer
La aprobación “De Novo” de BrainSee por parte de la FDA representa un gran avance en el diagnóstico de la enfermedad de Alzheimer. BrainSee establece un nuevo estándar para predecir la progresión del deterioro cognitivo leve amnésico (DCLa) a la demencia de Alzheimer mediante el uso de procesamiento de imágenes de última generación e inteligencia… Continue reading Darmiyan recibe la aprobación de la FDA para BrainSee, la primera prueba que permite predecir la probabilidad de progresión a la demencia de Alzheimer
Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer’s Dementia
FDA’s De Novo approval of BrainSee represents a major advancement in Alzheimer’s diagnostics. Utilizing cutting-edge image processing and medical AI, BrainSee establishes a new standard for predicting progression from amnestic mild cognitive impairment (aMCI) to Alzheimer’s dementia. This breakthrough is a significant step in proactive brain health management, offering a fully non-invasive, convenient, and globally… Continue reading Darmiyan Receives FDA Approval for BrainSee, the First Prognostic Test for Predicting Likelihood of Progression to Alzheimer’s Dementia
China’s EV stocks start 2024 in reverse gear as price wars pressure profitability
A BYD Seagull small electric car is on display during the 20th Shanghai International Automobile Industry Exhibition at the National Exhibition and Convention Center (Shanghai) Vcg | Visual China Group | Getty Images Shares of Chinese electric car makers have started the new year in reverse gear, as intense competition and continuing price wars pressure… Continue reading China’s EV stocks start 2024 in reverse gear as price wars pressure profitability
Summit Materials Shareholders Approve Combination with Argos USA
DENVER, Jan. 11, 2024 /PRNewswire/ — Summit Materials, Inc. (NYSE: SUM, “Summit” or the “Company”) announced today that its shareholders have voted overwhelmingly to approve certain proposals related to the Transaction Agreement, dated September 7, 2023 (the “Transaction Agreement”) by and among the Company, Argos North America Corp. (“Argos USA,” the U.S. operations of Cementos Argos… Continue reading Summit Materials Shareholders Approve Combination with Argos USA